Prophylactic antibiotics for massive endoprostheses in orthopaedic oncology: gaps in our understanding

Tariq Azamgarhi, S. Warren, Sarah Fouch, J. Standing, C. Gerrand

Research output: Contribution to journalArticlepeer-review

Abstract

The recently published Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial found no benefit in extending antibiotic prophylaxis from 24 hours to five days after endoprosthetic reconstruction for lower limb bone tumours. PARITY is the first randomized controlled trial in orthopaedic oncology and is a huge step forward in understanding antibiotic prophylaxis. However, significant gaps remain, including questions around antibiotic choice, particularly in the UK, where cephalosporins are avoided due to concerns of Clostridioides difficile infection. We present a review of the evidence for antibiotic choice, dosing, and timing, and a brief description of PARITY, its implication for practice, and the remaining gaps in our understanding.
Original languageEnglish
Pages (from-to)850-856
Number of pages7
JournalBone and Joint Journal
Volume105-B
Issue number8
DOIs
Publication statusPublished - 1 Aug 2023

Cite this